Litcius/Paper detail

315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Y. Kuboki, R. Yaeger, M.G. Fakih, J.H. Strickler, T. Masuishi, E.J. Kim, C.M. Bestvina, C.J. Langer, John C. Krauss, S. Puri, P. Cardona, E. Chan, Q. Tran, Dehan Hong

2022Annals of Oncology18 citationsDOI

Topics & Concepts

MedicinePanitumumabKRASColorectal cancerCohortRefractory (planetary science)OncologyInternal medicineCancerAstrobiologyPhysicsColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerGastric Cancer Management and Outcomes
315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort | Litcius